Innogen Pharmaceutical Widens H1 Loss; Shares Slip 6%

MT Newswires Live

09/01

Guangzhou Innogen Pharmaceutical (HKG:2591) widened its attributable loss in the first half of 2025 to 122.5 million yuan from 75.3 million yuan in the year-ago period, an Aug. 29 filing with the Hong Kong bourse said.

Shares of the pharmaceutical company were down 6% in Monday afternoon trading.

Loss per share rose to 0.29 yuan in the six months from 0.18 yuan in the corresponding period of the last year.

Revenue stood at 56.4 million yuan in the period, mainly from sales of Efsubaglutide Alfa in China.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564892561"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564892561\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564892561?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-01 15:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564892561","market":"sg","top_or_hot":-1,"title":"Innogen Pharmaceutical Widens H1 Loss; Shares Slip 6%","media":"MT Newswires Live","content":"<html><body><p> Guangzhou Innogen Pharmaceutical (HKG:2591) widened its attributable loss in the first half of 2025 to 122.5 million yuan from 75.3 million yuan in the year-ago period, an Aug. 29 filing with the Hong Kong bourse said.</p><p>Shares of the pharmaceutical company were down 6% in Monday afternoon trading.</p><p>Loss per share rose to 0.29 yuan in the six months from 0.18 yuan in the corresponding period of the last year.</p><p>Revenue stood at 56.4 million yuan in the period, mainly from sales of Efsubaglutide Alfa in China.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innogen Pharmaceutical Widens H1 Loss; Shares Slip 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnogen Pharmaceutical Widens H1 Loss; Shares Slip 6%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-01 15:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Guangzhou Innogen Pharmaceutical (HKG:2591) widened its attributable loss in the first half of 2025 to 122.5 million yuan from 75.3 million yuan in the year-ago period, an Aug. 29 filing with the Hong Kong bourse said.</p><p>Shares of the pharmaceutical company were down 6% in Monday afternoon trading.</p><p>Loss per share rose to 0.29 yuan in the six months from 0.18 yuan in the corresponding period of the last year.</p><p>Revenue stood at 56.4 million yuan in the period, mainly from sales of Efsubaglutide Alfa in China.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"銀諾醫藥－Ｂ","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2564892561","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564892561","pubTimestamp":1756712929,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guangzhou Innogen Pharmaceutical  widened its attributable loss in the first half of 2025 to 122.5 million yuan from 75.3 million yuan in the year-ago period, an Aug. 29 filing with the Hong Kong bourse said.Shares of the pharmaceutical company were down 6% in Monday afternoon trading.Loss per share rose to 0.29 yuan in the six months from 0.18 yuan in the corresponding period of the last year.Revenue stood at 56.4 million yuan in the period, mainly from sales of Efsubaglutide Alfa in China.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药－Ｂ"},"translate_title":"Innogen Pharmaceutical扩大上半年亏损；股价下跌6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":0.9},"content_text":"Guangzhou Innogen Pharmaceutical (HKG:2591) widened its attributable loss in the first half of 2025 to 122.5 million yuan from 75.3 million yuan in the year-ago period, an Aug. 29 filing with the Hong Kong bourse said.Shares of the pharmaceutical company were down 6% in Monday afternoon trading.Loss per share rose to 0.29 yuan in the six months from 0.18 yuan in the corresponding period of the last year.Revenue stood at 56.4 million yuan in the period, mainly from sales of Efsubaglutide Alfa in China.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}